Sentences with phrase «olaparib in»

The OPARATIC trial has paved the way for two additional clinical trials — PARADIGM and PARADIGM - 2 — testing olaparib in combination with radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.

A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Hence, a total of 90 patients from nine centers were randomly assigned to one of two study arms for the phase II clinical trial: the first taking capsules of olaparib (400 mg twice daily) and the other taking a combination of the two drugs (200 mg olaparib in capsule - form twice daily and 30 mg tablets of cediranib once daily).

«We are really excited to now be moving forward with the next phase of our trial, which will be a key step in the evaluation of olaparib in advanced prostate cancer.»

They found that cancer cells had acquired new genetic changes that cancelled out the original errors in DNA repair — particularly in the genes BRCA2 and PALB2 — that had made the cancer susceptible to olaparib in the first place.

Not exact matches

Olaparib is good at killing cancer cells that have errors in genes that have a role in repairing damaged DNA such as BRCA1 or BRCA2.

It could in future allow the PARP inhibitor olaparib to become a standard treatment for advanced prostate cancer, by targeting the drug at the men most likely to benefit, picking up early signs that it might not be working, and monitoring for the later development of resistance.

Olaparib was approved by the FDA in 2014 to treat ovarian cancers with BRCA mutations.

In particular, it has been shown that cells with other HR repair pathway defects, such as BRCA mutations frequently found in breast and ovarian cancer, are sensitive to inhibition of the enzyme PARP, and the PARP inhibitor Olaparib has been approved for treatment of BRCA - mutated ovarian cancerIn particular, it has been shown that cells with other HR repair pathway defects, such as BRCA mutations frequently found in breast and ovarian cancer, are sensitive to inhibition of the enzyme PARP, and the PARP inhibitor Olaparib has been approved for treatment of BRCA - mutated ovarian cancerin breast and ovarian cancer, are sensitive to inhibition of the enzyme PARP, and the PARP inhibitor Olaparib has been approved for treatment of BRCA - mutated ovarian cancers.

In tumors formed by human breast cancer cells, DNA damage (brown staining) is increased by simultaneous Olaparib treatment and PGAM1 suppression (right) when compared to either Olaparib treatment (left) or PGAM1 suppression (center) alone.

In this study, the researchers tested the effects of Olaparib on the tumors formed by human breast cancer cells injected into mice.

«The current options for maintenance therapy in the EU are bevacizumab, which can only be given once and improves progression - free survival by just a few months, and the PARP inhibitor olaparib, which is only approved in patients with a germline BRCA mutation (about 10 - 15 % of ovarian cancer patients).

Olaparib stopped prostate cancer growth, generating falls in prostate specific antigen (PSA) levels, falls in circulating tumour cell counts in the blood, and radiological responses on CT scans and MRI.

PARP (Poly ADP - Ribose Polymerase) inhibitors, such as olaparib, are targeted drugs that block an enzyme involved in many functions in the cell, including the repair of DNA damage.

«Our trial shows that olaparib is effective in men with defects in DNA repair genes who do not necessarily have an inherited risk of cancer — and that we can pick up these defects in the clinic.

Olaparib was licensed in December for women with ovarian cancer and inherited BRCA mutations, but the new research suggests it could also benefit men with genomic faults within their tumours.

An anti-angiogenic agent, or blood vessel inhibitor, called cediranib (which inhibits a protein known as VEGFR) and olaparib, a PARP inhibitor, are each clinically active in recurrent ovarian cancer.

The results will lead on to the start of TOPARP - B, a second part of the trial in which only men with detectable DNA repair mutations will receive olaparib.

In the trial, researchers monitored the response of 49 men with treatment - resistant, advanced prostate cancer to olaparib.

If the results of TOPARP - A are replicated in TOPARP - B, olaparib could become a treatment option in advanced prostate cancer.

«The findings of this study are exciting because they support the idea that combining these two targeted oral therapies results in significant activity in ovarian cancer, more so than olaparib alone,» said Joyce Liu, M.D., MPH, the lead investigator and medical oncologist at the Susan F. Smith Center for Women's Cancers at Dana - Farber Cancer Institute, Boston.

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination with AZD1775, AZD5363, or AZD2014 in Advanced Solid Tumors - OLAPCO (OLAParib COmbinations)

A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration - Resistant Prostate Cancer who have Failed Prior Treatment with a New Hormonal Agent and have Homologous Recombination Repair Gene Mutations.

A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma who have not received Prior VEGF Therapy

Olaparib targets a molecule called PARP, and exploits weaknesses in cancer cells» ability to repair damage to their DNA.

Tumours shrank in about 60 % of women who received the targeted drug, called olaparib (Lynparza), compared with 29 % of those who received chemotherapy.

A Randomized Phase 2 Study of Cediranib in Combination with Olaparib versus Olaparib Alone in Men with Metastatic Castration Resistant Prostate Cancer

An international research team, led by University College London's Professor Jonathan Ledermann, carried out a trial to see whether olaparib could have a role to play in preventing ovarian cancer from coming back in this group of patients.

Olaparib, taken in pill form, was designed to target cancers containing faulty BRCA1 and BRCA2 genes, while leaving healthy cells unharmed.

Cancer Research UK, who did not fund the trial but have played an important role in the development of PARP inhibitors like olaparib, said the results highlighted their potential.

Olaparib was also detected in 27 of 28 tumour margin specimens from 10 patients (mean concentration 500nM).

Researchers evaluated the maximum tolerated schedule and also measured olaparib exposure in tumour core, tumour margin and plasma following four doses.

«But these results suggest that olaparib is able to leak through because this barrier is disrupted in glioblastoma.

However, the mechanism of resistance in prostate cancer, and to PARPi other than olaparib, is unknown.

Olaparib resistance in patient 2 was associated with reversion mutations.

In ovarian or breast cancers, olaparib resistance has been associated with HRR restoration, including by BRCA2 mutation reversion.

Here, we identify BRCA2 reversion mutations associated with olaparib and talazoparib resistance in patients with prostate cancer.

Professor Susan Short, member of NCRI's Radiotherapy Research Working Group, said: «We're just beginning to realise the full potential of PARP inhibitors to tackle many different types of cancer, so it's exciting to see that olaparib could potentially be used to treat glioblastoma in combination with chemotherapy and radiotherapy.

** Olaparib was detected in 73 of 74 tumour core specimens from 27 patients (mean concentration: 588nM).

Here, we show BRCA2 reversion mutations in patients with prostate cancer with metastatic disease who developed resistance to talazoparib and olaparib.